REAL WORLD EVIDENCE IN GERMAN HTA: THE CHALLENGES OF COMPARATIVE ROUTINE PRACTICE DATA COLLECTION (ABD) FOR EARLY BENEFIT ASSESSMENT (AMNOG)

被引：0
|
作者：
Bogner, K. [1 ]
Ebentheuer, L. M. [1 ]
Wegener, M. [1 ]
Wuetner, S. [1 ]
机构：
[1] AMS Adv Med Serv GmbH, Mannheim, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA342
引用
收藏
页码：S386 / S386
页数：1
相关论文
共 20 条
  • [1] THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS
    Borchert, K.
    Loepmeier, J. F.
    Braun, S.
    Jacob, C.
    [J]. VALUE IN HEALTH, 2019, 22 : S795 - S795
  • [2] 10 YEARS OF AMNOG: IMPORTANCE OF REAL-WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT PROCESS
    Seidel, K.
    Schnaidt, S.
    Viering, T.
    Loepmeier, J. F.
    Borchert, K.
    Jacob, C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S314 - S314
  • [3] TRENDS IN THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS 2011-2019
    Borchert, K.
    Seidel, K.
    Loepmeier, J. F.
    Braun, S.
    Jacob, C.
    [J]. VALUE IN HEALTH, 2020, 23 : S666 - S666
  • [4] Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
    Makady, Amr
    van Veelen, Ard
    Jonsson, Pall
    Moseley, Owen
    D'Andon, Anne
    de Boer, Anthonius
    Hillege, Hans
    Klungel, Olaf
    Goettsch, Wim
    [J]. PHARMACOECONOMICS, 2018, 36 (03) : 359 - 368
  • [5] Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
    Amr Makady
    Ard van Veelen
    Páll Jonsson
    Owen Moseley
    Anne D’Andon
    Anthonius de Boer
    Hans Hillege
    Olaf Klungel
    Wim Goettsch
    [J]. PharmacoEconomics, 2018, 36 : 359 - 368
  • [6] Using real-world data (RWD) in health technology assessment (HTA) practice: A comparative study of 5 HTA agencies
    Makady, Amr
    van Veelen, Ard
    Jonsson, Pall
    Moseley, Owen
    D'Andon, Anne
    de Boer, Anthonius
    Hillege, Hans
    Klungel, Olaf
    Goettsch, Wim
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 91 - 91
  • [7] USING REAL-WORLD DATA (RWD) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) PRACTICE: A COMPARATIVE STUDY OF 5 HTA AGENCIES
    Makady, A.
    van Veelen, A.
    Jonsson, P.
    Moseley, O.
    D'Andon, A.
    de Boer, A.
    Hillege, J. L.
    Klungel, O.
    Goettsch, W.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A401 - A401
  • [8] Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies
    Makady, Amr
    ten Ham, Renske
    de Boer, Anthonius
    Hillege, Hans
    Klungel, Olaf
    Goettsch, Wim
    [J]. VALUE IN HEALTH, 2017, 20 (04) : 520 - 532
  • [9] POLICIES FOR USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT: A COMPARATIVE STUDY OF 6 HTA AGENCIES
    Makady, A.
    ten Ham, R.
    de Boer, A.
    Hillege, J. L.
    Klungel, O.
    Goettsch, W.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A501 - A502
  • [10] Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements
    Sievers, Hannah
    Joos, Angelika
    Hiligsmann, Mickael
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2021, 37 (01)
12